Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality
Martinez-Lopez et al.,
Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient..,
Blood Cancer Journal, doi:10.1038/s41408-020-00372-5
Retrospective 167 multiple myeloma patients in Spain, showing no significant difference in mortality with HCQ treatment in unadjusted results without group details.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
risk of death, 33.0% lower, RR 0.67, p = 0.20, treatment 47 of 148 (31.8%), control 9 of 19 (47.4%), NNT 6.4.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Martinez-Lopez et al., 30 Jun 2020, retrospective, Spain, peer-reviewed, median age 71.0, 25 authors.
Abstract: Martínez-López et al. Blood Cancer Journal (2020)10:103
https://doi.org/10.1038/s41408-020-00372-5
ARTICLE
Blood Cancer Journal
Open Access
Multiple myeloma and SARS-CoV-2 infection:
clinical characteristics and prognostic factors of
inpatient mortality
1234567890():,;
1234567890():,;
1234567890():,;
1234567890():,;
Joaquín Martínez-López 1, María-Victoria Mateos 2, Cristina Encinas3, Anna Sureda4, José Ángel Hernández-Rivas5,
Ana Lopez de la Guía6, Diego Conde7, Isabel Krsnik8, Elena Prieto9, Rosalía Riaza Grau10, Mercedes Gironella 11,
María Jesús Blanchard12, Nerea Caminos13, Carlos Fernández de Larrea14, María Alicia Senin15, Fernando Escalante16,
José Enrique de la Puerta 17, Eugenio Giménez18, Pilar Martínez-Barranco19, Juan José Mateos20, Luis Felipe Casado21,
Joan Bladé14, Juan José Lahuerta 1, Javier de la Cruz22 and Jesús San-Miguel 23
Abstract
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple
myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73
hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were
compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted
at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were
male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was
moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required
by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive
ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients,
inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at
hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent
prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies
predictors of inpatient mortality among MM patients hospitalized with COVID-19.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit